SCYNEXIS, Inc. (SCYX): Price and Financial Metrics
SCYNEXIS, Inc. (SCYX)
Today's Latest Price: $6.34 USD
Updated Dec 4 4:00pm
Add SCYX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SCYX Stock Summary
- With a price/sales ratio of 1,257.42, Scynexis Inc has a higher such ratio than 99.47% of stocks in our set.
- Revenue growth over the past 12 months for Scynexis Inc comes in at -77.73%, a number that bests only 1.83% of the US stocks we're tracking.
- The volatility of Scynexis Inc's share price is greater than that of 99.5% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Scynexis Inc, a group of peers worth examining would be GERN, CBMG, INO, MRSN, and ADAP.
- Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.
SCYX Stock Price Chart Interactive Chart >
SCYX Price/Volume Stats
| Current price | $6.34 | 52-week high | $12.10 |
| Prev. close | $6.20 | 52-week low | $4.20 |
| Day low | $6.25 | Volume | 56,800 |
| Day high | $6.44 | Avg. volume | 97,064 |
| 50-day MA | $5.29 | Dividend yield | N/A |
| 200-day MA | $6.95 | Market Cap | 69.36M |
SCYNEXIS, Inc. (SCYX) Company Bio
SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.
Loading social stream, please wait...